The Cellular Bases of Antibody Responses during Dengue Virus Infection
- 1Department of Cell Biology, Center for Advanced Research, The National Polytechnic Institute, Cinvestav-IPN, Mexico City, Mexico
- 2Department of Molecular Biomedicine, Center for Advanced Research, The National Polytechnic Institute, Cinvestav-IPN, Mexico City, Mexico
- 3Faculty of Biological and Chemical Sciences, Autonomous University of Sinaloa (UAS), Culiacan, Sinaloa, Mexico
- 4Department for Immunological Investigations, Institute for Epidemiological Diagnosis and Reference, Health Secretariat, Mexico City, Mexico
Dengue virus (DENV) is one of the most significant human viral pathogens transmitted by mosquitoes and can cause from an asymptomatic disease to mild undifferentiated fever, classical dengue, and severe dengue. Neutralizing memory antibody (Ab) responses are one of the most important mechanisms that counteract reinfections and are therefore the main aim of vaccination. However, it has also been proposed that in dengue, some of these class-switched (IgG) memory Abs might worsen the disease. Although these memory Abs derive from B cells by T-cell-dependent processes, we know rather little about the (acute, chronic, or memory) B cell responses and the complex cellular mechanisms generating these Abs during DENV infections. This review aims to provide an updated and comprehensive perspective of the B cell responses during DENV infection, starting since the very early events such as the cutaneous DENV entrance and the arrival into draining lymph nodes, to the putative B cell activation, proliferation, and germinal centers (GCs) formation (the source of affinity-matured class-switched memory Abs), till the outcome of GC reactions such as the generation of plasmablasts, Ab-secreting plasma cells, and memory B cells. We discuss topics very poorly explored such as the possibility of B cell infection by DENV or even activation-induced B cell death. The current information about the nature of the Ab responses to DENV is also illustrated.
Dengue virus (DENV) is one of the most significant human viral pathogens transmitted by mosquitoes and causes every year ~390 million infections worldwide, resulting in around 500,000 people with severe dengue (SD). It is estimated that over 50% of the world’s population is now at risk of dengue infection, caused by four serotypes (DENV1–4), which circulate in tropical and subtropical regions (1). It is believed that the vast majority of dengue infections are asymptomatic; however, a proportion manifests as a non-specific febrile illness or progresses to classical dengue fever (DF), characterized by fever and severe joint pain. Some of those infections can evolve to SD, such as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) (1). Neutralizing memory antibody (Ab) response is one of the most important mechanisms to defeat both homotypic and heterotypic reinfections with DENV and is therefore the aim of vaccines (2–5). However, one of the main hypotheses about SD revolves around class-switched memory Abs, in a mechanism referred to as Ab-dependent enhancement (ADE) of the infection (6). Although this mechanism has been studied in vitro, its potential importance in vivo is only beginning to be elucidated (7, 8). Classical epidemiological studies indicate that individuals having a secondary infection with a DENV serotype different to the first one are at increased risk of developing SD (9–11). This includes circumstances such as infants infected for the first time but who already bear maternally acquired DENV-specific Abs (12), which would predispose them to SD. While submitting this review, a report linked Zika virus infection with Guillain–Barré syndrome (13). Of note, there was concomitance of Zika infection, Guillain–Barré syndrome, and the presence of anti-DENV IgG Abs too, suggesting a relationship among these events. At least three preliminary scenarios are envisaged: (a) cross-reactive memory anti-DENV response may contribute to the Guillain–Barré syndrome (apparently discarded in the study), (b) anamnestic anti-dengue IgG responses might have been boosted by Zika in the Guillain–Barré syndrome, or (c) Zika induced cross-reactive Abs to DENV (13, 14). Of note, this is still preliminary and rather speculative, and more solid evidence is needed. What is clear, however, is that the involvement of Ab responses needs very careful scrutiny, and this recent finding highlights the importance of studying the B cell responses not only in DENV but also in these other emerging flaviviruses infections. It is conceivable that memory responses to DENV could be involved in these other flaviviruses diseases.
While T cell responses during acute DENV infection have been studied in some detail, much less is known about the complex mechanisms of B cell responses. Despite that memory Abs are generated by B cells, and that several recent elegant studies are still defining crucial features about the Abs to DENV [for instance, the antigenic epitopes that induce either neutralizing or non-neutralizing Abs (7, 8, 15)], we know surprisingly little about the B cell response itself, either during acute infection when disease is still manifested or regarding the mechanisms generating long-lived plasma cells (LLPCs) or memory B cells (MBCs). Herein, we provide an updated view of the immune response to DENV infection from the B cell perspective: since the early viral entrance into regional lymph nodes (LN) after cutaneous infection, highlighting B cell activation and proliferation or activation-induced B cell death, to the induction of germinal center (GC) B cells, plasmablasts (PBs), plasma cells (PCs), and MBCs, we also illustrate some current information about the cellular bases of the Ab response to DENV antigens (Ag) (Figure 1).
Figure 1. The B cell responses during DENV infection. Mosquitoes inoculate DENV mostly intradermally (1); inoculum is a mixture of mature (black circles) and immature (yellow circles) virions. DCs would capture DENV or DENV Ags and enter lymphatics (2) ferrying these Ags to regional DLNs (3). On the other hand, DENV could also reach the DLN via the lymph flow in a putative cell-free manner. Upon arrival into DLNs, viruses can encounter DENV-specific naive B cells and could generate short-lived PCs producing IgMs by a T-cell-independent extrafollicular B cell response (4) or could enter to a T-cell-dependent GC reaction (5). GCs will generate long-lived PCs and MBCs (6), which can produce a mixture of both neutralizing and cross-reactive DENV-specific Abs. These Abs would either neutralize the virus, containing the spread of infection (7) or enhance the infection of other targets cells, according to ADE (8). Cross-reactive non-neutralizing Abs seem to predominate in the memory response by MBCs (9). On the other hand, DENV may infect B cells “directly” either in circulation or in tissues such as in secondary lymphoid organs (10).
Dengue virus is an enveloped plus strand RNA virus whose genome encodes three structural proteins – capsid, envelope (E), and membrane (M) – and seven non-structural (NS) proteins – NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 (16, 17). Because M protein is first formed as a precursor called precursor M protein (prM), the maturation process of DENV is directed by the proteolytic cleavage of the prM, producing then totally mature infectious particles (18–20). However, this mechanism is not completely efficient, and fully immature or partially mature virions are produced by host cells. Immature status of virions depends on the prM cleavage, modifying size, and morphology of the particles (21). It is estimated that at least 30–40% of DENV particles released from infected mosquito cells are immature, containing different quantities of prM (22). Thus, in the first instance after viral entrance into the host, the immune system might recognize E, M, and prM Ags from DENV. It has been suggested that in the presence of non-neutralizing class-switched memory anti-prM Abs, even immature and non-infectious virus can enter to the cells via Fc gamma receptors (FcγR) and replicate efficiently, leading to more infected cells, potentially contributing to a more severe disease (23, 24). On the other hand, the structural protein E has three domains (EDI-III) (25), and it is known that EDIII is involved in the virus attachment to host cell surface (26). Also, it has been known that neutralizing Abs are preferentially directed to EDIII; however, recent findings indicate that Abs to E protein might facilitate DENV infection when present at subneutralizing concentrations (7, 15). Likewise, it has been also proposed that Abs to the whole protein E can also behave as facilitating ones by enhancing infectivity of immature or partially mature particles due to recognition of epitopes that are exposed in immature virions (27, 28). In addition to the potential facilitating effects of these Abs, those that are indeed neutralizers seem to be directed against complex conformational epitopes, which are expressed only when proteins are already assembled on a mature virus particle; therefore, it has been complicated to dissect the precise antigenic nature of these structures (2). Nonetheless, the currently preferred animal model to study the in vivo immune response to DENV infection is mostly limited to immune-deficient mice [a mouse deficient for both α/β and γ interferon receptors in a 129 background (AG129)] (29–31). However, to assess precisely the intact immune responses to DENV and – for instance – the generation of potentially neutralizing or non-neutralizing Abs to this virus, these animals might not be the best indicated model.
In addition to this, despite the fact that only the E protein is exposed on the surface of the fully mature virions, the antigenic structure of DENV is very complex, since there are conformational changes in DENV morphology along the replication cycle, such as the different structures found in mosquitoes and humans. Thus, the ideal DENV vaccine candidates should generate an optimal humoral response with Abs that bind to and neutralize the whole spectrum of viral structures (32).
B Cell Infection and Activation by DENV
For many years, monocytes were deemed the main primary target cells for DENV (33–35). However, the precise mechanisms of in vivo and in vitro infection of these cells are still controversial, and the percentage of circulating DENV-infected monocytes is too low (36). It could be that after activation, monocytes may get infected, since in circulation, they are mostly resting or immature (37, 38), thus somehow “resistant” or not permissive to the infection. Many reports have used these cells to assess ADE in vitro due to their FcγRs, obtaining an increased frequency of infection (34); nevertheless, the proportion of infected monocytes is still low. Being B cells, the ones responsible for the Ab responses, not much is known about their role during DENV infection or whether they could be themselves targets of DENV. Studies in vitro have shown that human lymphoblastoid cell lines with B cell characteristics were productively infected by DENV2 (39). Also, although many efforts have been done to elucidate the fraction of peripheral blood mononuclear cell (PBMC) infected with DENV during acute disease, there are no definite evidences yet and little is known about the cell types infected in vivo. There are reports that B cells are themselves targets of DENV infection. In particular, one study has identified B cells as the major DENV-infected cell population from the PBMCs. Cells were collected from acutely ill dengue patients and separated into subsets. The majority of the virus was recovered from the B cell subset, and this was irrespective of the DENV serotype. Interestingly, DENV was not recovered from monocytes or NK cells (40). It has also been shown that CD19+ cells increase during DENV infection and that these increments correlated with the presence of so-called atypical lymphocytes seen in Giemsa-stained blood films. These atypical lymphocytes were defined as large mononuclear cells having a fine homogeneous nuclear chromatin and a dark staining cytoplasm, some of these cells resembled blast cells. In addition, these atypical lymphocytes accounted for 10% or more of PBMCs in patients with DF or DHF (41). However, the origin of these atypical lymphocytes is still unclear, and B cells have been suggested as the source due to the increase of CD19+ cells in DHF patients (41, 42). It is possible that this population of atypical lymphocytes corresponds to PBs, since PBs responses seem to dominate the B cell compartment during DENV infection, as discussed below.
In another study (43), it was shown that B cells are the predominant DENV-infected cells in dengue patients, with 20–81% of CD19+ cells in the PBMCs containing DENV3. Nevertheless, other in vitro studies have found different results. For instance, human splenic macrophages, but neither T nor B cells, appeared to be permissive for DENV infection, and these splenic macrophages exhibited enhanced DENV infection in the presence of highly diluted DENV-immune human serum (44).
In a report analyzing one patient with DHF, it was possible to isolate two different genotypes of DENV2, and high levels of viral Ags were detected in peripheral B lymphocytes; one of the isolated viruses was capable of infecting and effectively multiplying in a B cell line. However, the other isolated virus did neither efficiently bind to nor was able to infect the B-cell line (45). It could be that the infection of B cells during dengue is dependent on the DENV genotype or serotype. Also, it is important to note that B cells might get infected via FcγRs if Abs indeed facilitate the invasion of host cells during secondary heterologous infections. In fact, from this perspective alone, not only B cells but also any cell bearing FcγRs is potentially susceptible of DENV infection.
Are B cells infected with DENV? Are they infected only in peripheral blood or in tissues too? There are few reports suggesting DENV infected B cells in tissues. Describing the distribution of the DENV-Ags in fatal cases in humans, the presence of viral Ags was found inside lymphoid organs. Positivity for DENV proteins has been found in blast cells inside B cell follicles, PCs, and B cells in spleen and LNs (46). The presence of positive-strand viral RNA has been related to viral replication in GC B cells from humans (47) (GCs will be described below). On the other hand, NS3, NS1, prM, and E viral proteins have been reported inside GCs in LNs from both humans and mice (48–50), suggesting infection of GC B cells. These findings showed DENV Ags inside lymphoid tissues, particularly inside GCs, suggesting a potential infection of B cells in these structures. Perhaps B cells during GC reactions express molecules that DENV can target as receptors to infect them. Nevertheless, it is feasible that DENV Ags reach B cell follicles by other routes (such as lymph, blood, or the complex intranodal conduit system), and the presence of DENV Ags inside B cell follicles does not necessarily indicate infection of B cells.
Altogether, these data suggest that B cells could indeed get infected by DENV, but are they activated by the virus or by other cells in the microenvironment during infection?
Analyzing the gene expression in B cells during their interaction with DENV in vitro, it was described that in response to this virus, B cells over-expressed several genes such as TRAIL, IP-10, and MCP-2 (51). Another report assessed the permissiveness of human B cells to DENV2 infection indicating active DENV2 replication, also that the infection induced IL-6 and TNF-α production by B cells. Furthermore, heterologous serum from patients infected with DENV3 was able to increase the proportion of DENV2-infected B cells and the cytokine production by these B cells (52).
During DENV infection, the interaction between infected and non-infected cells and the release of inflammatory mediators may play an important role in the outcome of the disease. Some reports have described the activation of B cells by other DENV-infected cells. For instance, it was described that murine splenic B cells can be efficiently activated in vitro and in vivo by DENV-infected peritoneal macrophages, leading to the clonal expansion of those B cells, as authors showed by counting the virus-specific IgM Ab plaque-forming cells (53). On the other hand, the help of T cells by direct cell contact, and the cytokines from macrophages were necessary, in vitro, for activation of splenic B cells (54). A/J inbred mice that were inoculated intravenously with a non-mouse-adapted DENV2 showed early activation of B lymphocytes and IgM production. These IgM-producing B cells may be important for clearing primary DENV infection (55), but more studies on this are needed.
In sum, many reports suggest that B cells are themselves infected by DENV, but this infection could depend on the serotype or genotype of the virus, as many other features of the infection, such as, for instance, the expression of FcγRs and the history of previous DENV infections. Moreover, it could be that either DENV or other infected-target cells, such as macrophages, might activate B cells that can then contribute to the release of inflammatory mediators. Thus, in addition to producing Abs, B cells may be playing an important role in activating the immune system or in inflammatory reactions during acute DENV infection.
Plasmablasts and Plasma Cells Responses during DENV Infection
Classical epidemiological studies indicate that SD is more common in secondary heterologous DENV infections (9–11), implying the involvement of immune mechanisms. Efforts to understand the immune bases of this SD have correlated cross-reactive class-switched (memory) non-neutralizing Abs from a previous infection with the enhancing effect upon new DENV-infected cells, among other mechanisms. These memory IgG Abs would be serotype cross-reactive and non-neutralizing. Since Abs derive from B cells, this implies that the mechanisms of B cell activation, maturation, and differentiation are important in determining the subsequent clinical outcome of the disease. Of note, these memory responses are dependent on T-cell help. The study of the basic cellular mechanisms for Ab production has been rather neglected in dengue. For instance, it was not until very recently that the potential role of PBs and PCs during DENV infection was evaluated, even when these latter cells are the actual Ab-producing cells. PBs responses in patients with acute DENV infection show a big increase over the levels observed in patients with other viral infections, such as influenza, and over the baseline levels found in non-infected healthy subjects (56–60). The global gene expression patterns in PBMCs isolated from DHF patients showed an enrichment of PBs signatures that was accompanied by an increase of PBs by FACS analysis (60). Of note, the amount of PBs is higher even in DENV-infected children than in control healthy subjects (59). As high numbers of PBs and PCs have been observed in dengue patients, this suggests increased Ab production. The numbers of PBs and PCs were higher in secondary than in primary dengue cases, suggesting re-activation of MBCs. In addition, DENV seems to activate polyclonal B cells that cross-react with other Ags, such as polio virus, since significant amounts of polio-reactive Abs were identified 15–25 days after fever in dengue patients compared to control subjects (56).
It is worth mentioning that PBs responses seem to overtly dominate the B cell compartment (often as much as 80% of the CD19+ cell population were PBs) during DENV infection, making up as much as 30% of the total peripheral lymphocytes (58). In contrast, influenza vaccine or primary vaccination with the yellow fever vaccine induced a much smaller PBs response, around 2–3% of the total B (CD19+) cells (61). The PBs during DENV infection are present in the peripheral circulation only for a relatively short time, undergoing contraction or migration to tissues where long-term Ab production can be sustained. However, only a small number of them survive long-term as LLPCs. It could be that the majority of the induced PBs is predestined to a short life span (58). The authors suggested that DENV could be inducing the surviving of cross-reactive B cells, since the increase in poly-serotype-specific PCs during a secondary DENV infection seem to be mediated by the cross-reactive MBCs formed during prior heterologous infections (59, 62).
Although in some cases PBs show a strong polyclonal response to the E protein, their specificity is not representative of the serum Abs secreted by LLPCs in the memory phase (63). In search of a potential dengue-specific genetic pattern regarding the usage of V and J genes for both H and L chain, it was described in DENV-specific and non-specific PBs isolated from secondary infections, that DENV-specific PBs showed a preference for VH1 family, whereas VH3 gene usage was dominant in MBCs (63). Authors suggested that DENV might selectively bind to B cells using rather unusual V family genes and these B cells would be efficiently activated and differentiate into PBs during acute disease. Compared with the pauci-clonal response seen to influenza vaccines in subjects with pre-existing immunity, PBs responses to DENV infection were relatively polyclonal (61, 63).
Considering the neutralizing Ab responses to DENV, the data suggest that after secondary infections, neutralizing Abs are produced by newly activated B cells. This is because there is an increased response by cross-reactive MBCs producing cross-reactive and non-neutralizing Abs, which would rather enhance the infection instead of controlling it (56). According to this, the neutralizing Abs would be produced by recently activated B cells. Understanding the nature of activated or re-activated B cells is of particular relevance in the context of efficient and safer human vaccination efforts. It will be important to determine the extent to which defined Ag-specific PBs clones are selected from the memory pool and whether they modify their specificity or affinity in the memory phase, as this could help to determine more accurate correlates of protection (63). It is unknown whether a secondary encounter during a heterologous DENV infection will modify the affinities from the cross-reactive MBCs generated during the first GC reactions.
Additionally to an association of high PBs numbers with severe secondary DENV infection and with the production of memory Abs that cross-react with heterotypic DENV serotypes, DENV also induces B cell activation, proliferation, and cell death, mostly in patients with SD, suggesting that DENV infection promotes activation-induced B cell death and perhaps increased B cell turnover. Cell death has been determined by the expression of caspase-3, a marker of apoptosis, and by the increased expression of the pro-apoptotic marker CD95 (57). Analyzing the apoptotic genes upregulated in PBMCs during the acute phase of natural DENV infection, in patients with SD, it was found the upregulation of the B cell translocation gene 1 (BTG1), and of many other apoptotic genes in B cells. However, it was not analyzed which PBMCs subsets underwent apoptosis (64). Another report showed that an apoptotic CD8+ T cell population is increased among the apoptotic PBMCs in patients with SD, but apoptosis in the B cell fraction was not examined (65). Is DENV inducing death in B cells? Is apoptosis the mechanism for this cell demise? Of note, apoptosis is a “silent” form of death that prevents, rather than promotes, inflammation. Is this activation-induced B cell death an advantageous mechanism for the virus to successfully establish the infection or to avoid overt inflammation by inducing apoptosis?
The gene expression pattern in the PBs fraction of PBMCs from DHF patients showed that the cell cycle/endoplasmic reticulum gene cluster displayed a strong positive correlation with CD19+ lymphocytes. Flow cytometry analysis revealed that most PBs/PCs also expressed the cell cycle-associated nuclear Ag Ki67, indicating that they were indeed proliferating (60). Genes associated with the regulation of apoptosis were also found among the group whose transcripts were more abundant during early DENV infection, which correlates with the expression of apoptosis markers such as caspase-3 and Fas in PBs and B cells (57, 60). Altogether, the data suggest that DENV induces a strong B cell response dominated by cross-reactive PBs during the acute phase of the infection; this response includes cell proliferation and cell death, apparently by non-inflammatory apoptosis, and also an increased B cell turnover.
It is important to highlight that, despite the difficulties, the majority of reports on B cell responses during DENV infection is based on human samples. Trying to overcome some of these complications, other studies with DENV have used animal models, for instance, mice; however, very few findings have been reported regarding the B cell responses. In one of them, DENV-infected mice were challenged with LPS, and the Ab response against this molecule was evaluated. The response to LPS was significantly lower in DENV-infected mice in comparison with animals inoculated with control conditions such as inactivated DENV. These results suggest that DENV infection in mice may decrease intrinsic B-cell functions and that this immune “suppression” might be caused by active viral replication and not by the viral Ags themselves, since the administration of inactivated DENV failed to cause this decreased immune response (66).
Another study showed that after secondary DENV infections in the immune-deficient murine model (AG129 mice), increased DENV-specific avidity in Abs was not associated with increased DENV-specific neutralizing Abs, whose production appears to be mediated by naive B cells (67).
It is important to emphasize that despite the fact that class-switched PBs, PCs, and MBCs are generated and selected mostly in GC reactions, so far, there are no studies about the potential involvement (or not) of GCs during DENV infection. The GC is a very complex microenvironment, where clonal B cell expansion and selection occurs in response to T-cell-dependent Ags. Two crucial molecular mechanisms are utilized in the GCs, somatic hypermutation and class-switch recombination. The outcome of the GC reaction is the generation of long-lived, high-affinity Ab-secreting cells/PCs, and MBCs, thus developing both immediate and long-term protection against re-infections (68–70). However, we do not know how the affinity is modified, especially during secondary homologous and heterologous DENV infections. Our group has recently shown that cutaneously delivered DENV has the ability to infect immune-competent mice inducing a strong GC response. The overall outcome of these GC responses seems a bigger quantity of prM-specific GC B cells and a higher titer of Abs to prM than those to the E viral protein (50). It is conceivable that DENV proteins might be inducing both neutralizing and non-neutralizing memory Abs; some of these (the non-neutralizing ones) would potentially enhance the infection of other target cells via FcγRs, according to the ADE hypothesis, thus ensuring successful secondary heterologous infections. Moreover, it is unknown whether cross-reactive memory Abs from the first DENV encounter modify the activation, affinity maturation, and selection of B cells during GC reactions in heterologous subsequent DENV infections.
Primary B Cell Responses and IgM Abs during DENV Infection
On first encounters with hosts, most pathogens will elicit a primary humoral immune response characterized by an early rise of Ag-specific IgM Abs in a T-cell-independent extrafollicular reaction, and if complex circumstances allow it, this might be followed by affinity maturation, isotype Ab switching, and the ensuing increase of Ag-specific IgG, IgA, or IgE Ab titers, but now in a T-cell-dependent manner (71). For instance, primary IgM Abs provide protection, and their absence in influenza-infected mice triggered increased viral loads in the lungs, with significantly reduced levels of virus-specific IgG1 and IgG2a Abs (72). Of note, despite the fact that DENV-specific IgM has long been used as diagnosis for DENV infection (73), the precise B cell source and the putative effector mechanisms of these IgM Abs are unclear. IgM Abs could come from several possible B cell sources such as from extrafollicular reactions by B1 B cells, from transitional B cells, or from marginal zone (MZ) B cells in humans and mice – besides follicular B or B2 cells by extrafollicular reactions in a T-cell-independent mechanism (74–77). Although it has been less explored, some reports suggest that IgM-PCs could also come from follicular responses through GC reactions (78–80). Transitional B cells correspond to the most immature B cell type in the peripheral blood (74), while MZ B cells are B cells identified in the MZ of the spleen only (76). On the other hand, B1 B cells constitute a distinct B cell lineage, are part of the innate immune response, and generate effectors rapidly in the first stages of a humoral immune response (81). However, these possibilities have been barely explored during natural or experimental DENV infections.
As mentioned before, very few studies have focused on primary “natural” Abs during DENV infection, as an example, IgM can be found in secondary infections although, commonly, the average titers are lower than in primary ones (82). However, it has been reported that the human IgM response to DENV could be predominantly cross-reactive among DENV serotypes, and this IgM response is significantly higher in patients with SD than in patients with DF (acute phase) (83–85). Additionally, although it has been described that some IgM Abs have the ability to neutralize DENV, the epitopes that they are recognizing seem rather discontinuous or conformational (86).
Also, in the sera of DENV patients, it is possible to find IgM Abs cross-reacting with platelets, a finding which may contribute to explain in part DENV pathogenesis. Due to the polyclonal B cell activation that DENV would be causing, this could lead to IgM production (56, 83), but the cells producing these IgM Abs have not been assessed. In humanized BLT-NSG (NOD-scid IL2rγnull mice) immune-deficient mice, the Ab response was characterized by the lack of production of DENV-specific IgG but by the presence of DENV-specific IgM-secreting B cells, perhaps due to an elevated number of immature (transitional) B cells in the periphery (87). Research on primary “natural” Ab responses to DENV has been overlooked, and further studies are needed to elucidate their role during the infection, either in virus clearance or in pathogenesis. Despite the cross-reactivity of IgM Abs to DENV serotypes, apparently, they are not contributing to enhance the infection (88). However, they could be involved in the development of pathogenesis, as they can recognize self-Ags in platelets. It would seem that the enhancing properties of the Abs are restricted to the class-switched (IgG) memory ones.
Efforts to elucidate how is it that putative non-neutralizing memory Abs could enhance the disease have described in vitro using cell lines that through subneutralizing or non-neutralizing Abs, DENV infection suppresses innate cell immunity via FcγRs, thus facilitating viral replication (89–91). Similar experiments in human primary cell cultures seem to provide different pathways to enhance the infection by DENV via FcγRs (92, 93). Nonetheless, whether these mechanisms depend on particular FcγRs is still unclear (94, 95). Data from in vitro studies indicate that any specificity of monoclonal Abs to dengue might form infectious immune complexes (ICs), the major requirement being Ab concentration below that needed for neutralization (94, 96). To this respect, it has been described that the density of Ag-IgGs and FcγRs cross-linked on macrophages might influence phagocytosis and IL-10 production (97). Something similar could be happening in DENV infection.
Long-Term (Memory) B Cell Responses and Memory Abs during DENV Infection
Regarding B cell biology, perhaps the most important function of B cells is to become Ab-producing cells. There are many good studies about Abs during DENV infection and recently about the DENV epitopes that induce them. However, the results have been somehow puzzling since neutralizing memory Abs make up a small fraction of the anti-DENV neutralization activity in human immune sera (4, 7, 8, 15, 98). Furthermore, certain Abs have been related to enhancing the infection in the mechanism called ADE, where memory Abs from a primary infection would be enhancing a secondary heterologous DENV infection (6). Only very recently were the first findings published over DENV epitopes that define the Ab responses in humans, as well as the mechanisms that the virus seems to use to infect host cells (7, 8, 15). Non-neutralizing memory Abs could render immature DENV particles infectious; thus, non-infectious viruses can enter via FcγRs and replicate efficiently, leading to more infected cells, potentially contributing to a more severe disease (23, 24).
Memory Abs, which are present before a secondary antigenic exposure occurs, constitute a very powerful evolutionary (anticipatory) strategy to cope with potential subsequent infections; this may allow the neutralization of a given pathogen before a second infection is well established (99). MBCs are the ones implicated in the Ag recall response and are rapidly activated during a secondary infection. MBC activation is faster, thus providing rapid protection against re-exposure to potentially dangerous Ags when MBCs differentiate to PCs and generate long-lasting B cell immunity (100). Released memory Abs by these PCs should neutralize DENV, as would be the case in homologous reinfections. However, during heterologous DENV reinfections, some LLPCs and MBCs might be apparently “responsible” for producing infection-facilitating Abs (101–103), an important issue that still needs to be well clarified. It has not been assessed in DENV infection how the affinity maturation develops during the first encounter with the virus and whether the affinity of MBCs is modified during a secondary heterologous infection.
Memory IgG Abs are generated mainly through T-cell-dependent reactions. Many of the non-neutralizing class-switched memory Abs during DENV infection are directed against epitopes found mainly on immature particles, such as the prM and E Ags (7, 8, 15, 27, 28, 104). These potentially enhancing-infection and non-neutralizing Ab responses are the dominant functional activities that are noted for the DENV-specific Abs encoded by MBCs, which predominate in the circulation even two or more decades following DENV infection (103). In addition, even neutralizing Abs may act, at least in vitro, as enhancers when at subneutralizing concentrations (7, 15, 102, 103). Furthermore, neutralizing class-switched memory Abs make up a small fraction of the anti-DENV binding and neutralization activity in human immune sera and are preferentially directed to EDIII (4, 7, 8, 15, 98). Interestingly, the most potent neutralizing DENV serotype-specific Abs bound to complex conformational epitopes found only on the intact viral particles (2, 5, 101, 102).
It has been reported that the B cell response detected early after primary DENV infection is predominantly serotype-specific, whereas responses detected early after secondary infection are predominantly serotype cross-reactive (56, 59). Abs detected during secondary infection recognize multiple serotypes of DENV E protein and have higher avidity to heterologous epitopes. Even after DENV infection, it is possible to observe in post-convalescent patients (6 months after primary infection) B cells reactive to heterologous E proteins at late time points, which were absent earlier (during the acute phase) (62). Additionally, PBs, which were generated from a very diverse, affinity-matured, and selected pool of MBCs and that did not proliferate extensively before differentiating into PBs, can also lead to the loss of dengue specificity because of this limited proliferation (63). Therefore, we might ask: is DENV inducing a preferential survival and/or generation of cross-reactive MBCs in order to ensure a successful infection during secondary encounters?
In the case of the last DENV vaccine (CYD-TDV), although few data are available on the generation of long-term immune memory, very recently, it was found in individuals after 5 years of vaccination, that DENV-specific MBCs are scarce in blood and secrete low amounts of Abs when stimulated. The circulating Abs showed low titers 5 years after vaccination, and these Abs from vaccinated individuals had limited in vivo efficacy against DENV2. Although the sample size was too small for definite conclusions, immune memory after vaccination with CYD-TDV appears relatively low (105).
How are the DENV Ags Reaching the B Cell Follicles Inside the Regional (Draining) Lymph Nodes?
As mentioned before, cutaneously inoculated DENV does infect immune-competent mice and induces a strong GC response (50). On the other hand, long-lasting MBCs are generated through GCs (69), and DENV Ags inside B cell follicles are likely needed to drive these GC responses. However, it is not clear how DENV or DENV Ags are reaching first the draining lymph nodes (DLNs) regional to the inoculation site and then the B cell follicles inside these regional nodes. Indeed, it is still unclear, and under much recent scrutiny, how is it that many other Ags reach the follicles and initiate the activation of B cells. Some mechanisms have been described highlighting where and how follicular B cells encounter Ags. First is how Ags are reaching the DLNs; to this respect, it is known that Ag size is a major factor, e.g., particulate Ags (for instance, vesicular stomatitis virus, inert beads coated with Ag, etc.) and large ICs are bound by subcapsular sinus (SCS) macrophages. These macrophages act as sentinels to uptake incoming Ags and pathogens entering via the afferent lymph, and in some cases, they shuttle these Ags to underlying B cells (106–109). Murine macrophages of the LN SCS facilitate B cell activation in vivo by collecting and displaying native Ags (108, 110). By contrast, small Ags (under 70 kDa) are rapidly channeled into follicles via conduits. LN conduits constitute an effective fluid shunt between the SCS and the blood-vessel lumen where low-molecular-weight substances reach the lumen of high endothelial venules (111). It is proposed that either small Ags enter the follicles via small gaps in the floor of the LN sinus where they are bound by cognate B cells or that the majority of lymph-borne Ag enters the follicles through conduits first (107, 112, 113). Results have also demonstrated that cognate B cells could take up Ags directly from the conduits, possibly at the gaps between the fibroblastic reticular cells and the conduit, as identified by electron microscopy (107).
On the other hand, regarding the distribution of Ags inside the DLN, it is important if the encounter with that Ag is for the first time or if it is a second encounter with the same Ag. Studies on early Ag capture showed that while most Ags are trapped and degraded in the medullary region during their first encounter, in a subsequent challenge, Ag–Ab complexes are initially trapped in the floor of the SCS (114, 115). In both cases, small amounts of Ag manage to infiltrate the follicle and can be retained there on follicular dendritic cells (FDCs) for prolonged periods of time (115, 116). SCS macrophages capture and present intact Ag in the form of ICs, viruses, and virus-like particles, to activate follicular B cells (106, 108, 109). However, how is it that naive B cells are activated upon the first Ag encounter, and how they “decide” to go into the follicles to undergo GC reactions – or not – is still unclear for many Ags and completely unknown for DENV.
Moreover, classical studies have been very instructive describing the uptake of Ags by FDCs (116). FDCs are more prominent during GC reactions, and FDC retention of Ags is essential for clonal selection of B cells within GC (107). Whether Ag retention is also required for maintenance of DENV memory and effector B cells is not clear. Some studies support a role for Ag persistence in the maintenance of B cell memory (107, 117). However, how and whether DENV Ags are localized or persist on FDCs during primary or secondary infections is unknown. Are DENV Ags retained on FDCs after a primary DENV infection? And – if so – for how long? Do they participate in the affinity maturation and selection of B cells and in the generation of cross-reactive Abs during a secondary heterologous infection?
In the immune-deficient murine model (AG129 mice), it has been shown that macrophages from the SCS are important controlling the spreading of the DENV. These SCS macrophages contained NS1 protein, likely implying that they are trapping DENV Ags (118). Furthermore, we have shown the presence of E, prM, and NS3 DENV proteins inside B cell follicles and GCs, indicating that DENV Ags are indeed reaching DLNs and also raising the possibility that DENV might be even replicating in these lymphoid tissue compartments (50). However, how DENV Ags are finally reaching the LNs is not clear. We and others have found DENV-infected cutaneous dendritic cells (DC) in human cadaveric and non-cadaveric healthy skin explants infected ex vivo (119–121). DCs are specialized sentinel cells that uptake Ags at peripheral sites and travel to DLNs ferrying them to DC areas where B cells migrating toward the follicles are also likely to encounter these Ags (122). It is highly likely that DENV might be reaching DLNs also through cutaneous DCs or by the lymphatic circulation, but this needs to be formally demonstrated as almost nothing has been explored on this regard. Very recently, by flow cytometry, it was possible to find in intradermally DENV-infected immune-deficient mice [IFN-α/β receptor knockout (IFNAR) mice], migratory DENV-infected DCs in the skin-draining node. This suggests that dermal DCs may be carrying DENV and probably initiating the adaptive antiviral immune response (121). However, exactly where (and how) is DENV localized inside DLNs after cutaneous infection has not been evaluated. It is possible that DENV-infected DCs localize in the interfollicular zone or in the T-cell zone inside the DLNs, which would allow the activation of both follicular and extrafollicular B cells.
To explore how DENV (from the skin) might be reaching the DLNs, we did preliminary experiments tracking labeled DENV or ovalbumin (OVA, as a control) upon cutaneous inoculation. As reported by others (123, 124), OVA was found in the SCS of DLNs very early (1 h) after inoculation, but not DENV, which was only seen later in DLNs (unpublished data). Double labeling revealed that macrophages were apparently trapping DENV when it arrived into DLNs, either by lymph or in cells that might transfer the Ag to macrophages. Conceivable, skin-infected DCs might be ferrying DENV directly into DLNs (121). All this would suggest that skin-derived DENV enters DLN via lymph and that at rather early stages, incoming DENV seems contained by macrophages in the subcortical area, a phenomenon also described for other Ags such as Salmonella adelaide flagella (114).
Despite the fact that Ab responses are generated by B cells, we know surprisingly little about the (acute, chronic, or memory) B cell responses and the cellular mechanisms generating these Abs during DENV infections, both in humans and in animal models. It is assumed that B and T cells participate in both the protection and possibly in the putative enhancement of the disease. To know which epitopes are driving the different Ab responses and how is it that higher or lower Ab affinities are established during infection and whether these events influence protection or pathogenesis during the disease, could be very useful to design more efficient, and particularly in the case of dengue, safer vaccines. This might be especially relevant in the current situation of concomitant virus infections, such as Zika and Chikungunya, where the potential involvement of the immunological memory to DENV in the outcome of these infections needs to be clarified. Of note, it was described recently that the more advanced DENV vaccine (CYD-TDV) “is walking a tightrope” as the short-term safety profile was benign [the efficacy reported at the beginning of the clinical trials was 30.2% (125)], but upon 25 months of disease surveillance, it was difficult to withdraw definite conclusions (126, 127). Besides, prior immunity seems needed to the efficacy of this vaccine (125, 126). We need to understand better these findings before this vaccine can be declared safe. Thus, a major comprehension of the B cell responses in their different stages and compartments during natural DENV infections is critical to develop strategies to better counteract the upsurging, not only of DENV infections but also of other related emerging viral diseases.
Conceived the topics and designed the paper: JY-P and LF-R. Wrote and revised the paper: JY-P, LC-B, EA-M, RR-P, AE-G, and LF-R. Final approval of the version to be published: LF-R.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
JY-P was a fellow-holder from CONACYT. LC-B, EA-M, RR-P, AE-G, and LF-R are members of the National System of Researchers, SNI-CONACYT.
This work was supported by a grant from the National Council for Science and Technology-CONACYT Mexico (221102) to LF-R; grant from Fonsalud (233347) to LC-B; grant from CONACYT (139542) to AE-G; and grants from CONACYT (207152) and PROFAPI-2014/004 to EA-M and RR-P.
ADE, antibody-dependent enhancement; DC, dendritic cell; DENV, dengue virus; DHF, dengue hemorrhagic fever; DLN, draining lymph node; DSS, dengue shock syndrome; E, envelope; EDI-III, envelope domain I-III; FcγR, Fc gamma receptor; FDC, follicular dendritic cell; GC, germinal center; IC, immune-complex; LLPC, long-lived plasma cell; M, membrane; MBC, memory B cells; MZ, marginal zone; NS, non-structural; OVA, ovalbumin; PB, plasmablast; PC, plasma cell; prM, precursor membrane; SCS, subcapsular sinus; SD, severe dengue.
1. World Health Organization. Dengue and Severe Dengue (2014) [cited 2014 July]. Available from: http://www.who.int/mediacentre/factsheets/fs117/en/
2. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 109(19):7439–44. doi: 10.1073/pnas.1200566109
4. Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, Isern S, et al. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J (2010) 7:28. doi:10.1186/1743-422X-7-28
5. Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, Yip A, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med (2012) 4(139):139ra83. doi:10.1126/scitranslmed.3003888
7. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 8(3):271–83. doi:10.1016/j.chom.2010.08.007
8. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science (2010) 328(5979):745–8. doi:10.1126/science.1185181
10. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med (1970) 42(5):311–28.
12. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg (1988) 38(2):411–9.
13. Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet (2016) 387:1531–9. doi:10.1016/S0140-6736(16)00562-6
15. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis (2011) 5(6):e1188. doi:10.1371/journal.pntd.0001188
16. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 108(5):717–25. doi:10.1016/S0092-8674(02)00660-8
18. Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, Chen J, et al. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science (2008) 319(5871):1830–4. doi:10.1126/science.1153263
19. Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, Chipman PR, et al. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science (2008) 319(5871):1834–7. doi:10.1126/science.1153264
21. Junjhon J, Edwards TJ, Utaipat U, Bowman VD, Holdaway HA, Zhang W, et al. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol (2010) 84(16):8353–8. doi:10.1128/JVI.00696-10
22. van der Schaar HM, Rust MJ, Waarts BL, van der Ende-Metselaar H, Kuhn RJ, Wilschut J, et al. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol (2007) 81(21):12019–28. doi:10.1128/JVI.00300-07
23. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, Wilschut J, et al. Immature dengue virus: a veiled pathogen? PLoS Pathog (2010) 6(1):e1000718. doi:10.1371/journal.ppat.1000718
26. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol (2001) 75(16):7769–73. doi:10.1128/JVI.75.16.7769-7773.2001
27. da Silva Voorham JM, Rodenhuis-Zybert IA, Ayala Nunez NV, Colpitts TM, van der Ende-Metselaar H, Fikrig E, et al. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS One (2012) 7(3):e29957. doi:10.1371/journal.pone.0029957
32. Zhang X, Sheng J, Plevka P, Kuhn RJ, Diamond MS, Rossmann MG. Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A (2013) 110(17):6795–9. doi:10.1073/pnas.1304300110
35. Valero N, Mosquera J, Levy A, Anez G, Marcucci R, Alvarez-Mon M. Differential induction of cytokines by human neonatal, adult, and elderly monocyte/macrophages infected with dengue virus. Viral Immunol (2014) 27(4):151–9. doi:10.1089/vim.2013.0123
36. Kou Z, Quinn M, Chen H, Rodrigo WW, Rose RC, Schlesinger JJ, et al. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol (2008) 80(1):134–46. doi:10.1002/jmv.21051
39. Theofilopoulos AN, Brandt WE, Russell PK, Dixon FT. Replication of dengue-2 virus in cultured human lymphoblastoid cells and subpopulations of human peripheral leukocytes. J Immunol (1976) 117(3):953–61.
40. King AD, Nisalak A, Kalayanrooj S, Myint KS, Pattanapanyasat K, Nimmannitya S, et al. B cells are the principal circulating mononuclear cells infected by dengue virus. Southeast Asian J Trop Med Public Health (1999) 30(4):718–28.
41. Jampangern W, Vongthoung K, Jittmittraphap A, Worapongpaiboon S, Limkittikul K, Chuansumrit A, et al. Characterization of atypical lymphocytes and immunophenotypes of lymphocytes in patients with dengue virus infection. Asian Pac J Allergy Immunol (2007) 25(1):27–36.
43. Baclig MO, Gervacio LT, Suarez LA, Buerano CC, Matias RR, Kumatori A, et al. Flow cytometric analysis of dengue virus-infected cells in peripheral blood. Southeast Asian J Trop Med Public Health (2010) 41(6):1352–8.
44. Blackley S, Kou Z, Chen H, Quinn M, Rose RC, Schlesinger JJ, et al. Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. J Virol (2007) 81(24):13325–34. doi:10.1128/JVI.01568-07
45. Kinoshita H, Mathenge EG, Hung NT, Huong VT, Kumatori A, Yu F, et al. Isolation and characterization of two phenotypically distinct dengue type-2 virus isolates from the same dengue hemorrhagic fever patient. Jpn J Infect Dis (2009) 62(5):343–50.
46. Bhoopat L, Bhamarapravati N, Attasiri C, Yoksarn S, Chaiwun B, Khunamornpong S, et al. Immunohistochemical characterization of a new monoclonal antibody reactive with dengue virus-infected cells in frozen tissue using immunoperoxidase technique. Asian Pac J Allergy Immunol (1996) 14(2):107–13.
47. Jessie K, Fong MY, Devi S, Lam SK, Wong KT. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis (2004) 189(8):1411–8. doi:10.1086/383043
48. Aye KS, Charngkaew K, Win N, Wai KZ, Moe K, Punyadee N, et al. Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Hum Pathol (2014) 45(6):1221–33. doi:10.1016/j.humpath.2014.01.022
49. Balsitis SJ, Coloma J, Castro G, Alava A, Flores D, McKerrow JH, et al. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am J Trop Med Hyg (2009) 80(3):416–24.
50. Yam-Puc JC, Garcia-Cordero J, Calderon-Amador J, Donis-Maturano L, Cedillo-Barron L, Flores-Romo L. Germinal center reaction following cutaneous dengue virus infection in immune-competent mice. Front Immunol (2015) 6:188. doi:10.3389/fimmu.2015.00188
51. Becerra A, Warke RV, Martin K, Xhaja K, de Bosch N, Rothman AL, et al. Gene expression profiling of dengue infected human primary cells identifies secreted mediators in vivo. J Med Virol (2009) 81(8):1403–11. doi:10.1002/jmv.21538
52. Lin YW, Wang KJ, Lei HY, Lin YS, Yeh TM, Liu HS, et al. Virus replication and cytokine production in dengue virus-infected human B lymphocytes. J Virol (2002) 76(23):12242–9. doi:10.1128/JVI.76.23.12242-12249.2002
55. Shresta S, Kyle JL, Robert Beatty P, Harris E. Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology (2004) 319(2):262–73. doi:10.1016/j.virol.2003.09.048
56. Balakrishnan T, Bela-Ong DB, Toh YX, Flamand M, Devi S, Koh MB, et al. Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection. PLoS One (2011) 6(12):e29430. doi:10.1371/journal.pone.0029430
57. Garcia-Bates TM, Cordeiro MT, Nascimento EJ, Smith AP, Soares de Melo KM, McBurney SP, et al. Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients. J Immunol (2013) 190(1):80–7. doi:10.4049/jimmunol.1103350
58. Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol (2012) 86(6):2911–8. doi:10.1128/JVI.06075-11
59. Zompi S, Montoya M, Pohl MO, Balmaseda A, Harris E. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis (2012) 6(3):e1568. doi:10.1371/journal.pntd.0001568
60. Simmons CP, Popper S, Dolocek C, Chau TN, Griffiths M, Dung NT, et al. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis (2007) 195(8):1097–107. doi:10.1086/512162
61. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 453(7195):667–71. doi:10.1038/nature06890
62. Mathew A, West K, Kalayanarooj S, Gibbons RV, Srikiatkhachorn A, Green S, et al. B-cell responses during primary and secondary dengue virus infections in humans. J Infect Dis (2011) 204(10):1514–22. doi:10.1093/infdis/jir607
63. Xu M, Hadinoto V, Appanna R, Joensson K, Toh YX, Balakrishnan T, et al. Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes. J Immunol (2012) 189(12):5877–85. doi:10.4049/jimmunol.1201688
64. Jaiyen Y, Masrinoul P, Kalayanarooj S, Pulmanausahakul R, Ubol S. Characteristics of dengue virus-infected peripheral blood mononuclear cell death that correlates with the severity of illness. Microbiol Immunol (2009) 53(8):442–50. doi:10.1111/j.1348-0421.2009.00148.x
65. Myint KS, Endy TP, Mongkolsirichaikul D, Manomuth C, Kalayanarooj S, Vaughn DW, et al. Cellular immune activation in children with acute dengue virus infections is modulated by apoptosis. J Infect Dis (2006) 194(5):600–7. doi:10.1086/506451
67. Zompi S, Santich BH, Beatty PR, Harris E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol (2012) 188(1):404–16. doi:10.4049/jimmunol.1102124
72. Baumgarth N, Herman OC, Jager GC, Brown LE, Herzenberg LA, Chen J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med (2000) 192(2):271–80. doi:10.1084/jem.192.2.271
73. Bundo K, Igarashi A. Antibody-capture ELISA for detection of immunoglobulin M antibodies in sera from Japanese encephalitis and dengue hemorrhagic fever patients. J Virol Methods (1985) 11(1):15–22. doi:10.1016/0166-0934(85)90120-X
74. Capolunghi F, Cascioli S, Giorda E, Rosado MM, Plebani A, Auriti C, et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol (2008) 180(2):800–8. doi:10.4049/jimmunol.180.2.800
76. Oliver AM, Martin F, Kearney JF. IgMhighCD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. J Immunol (1999) 162(12):7198–207.
77. Pulendran B, Smith KG, Nossal GJ. Soluble antigen can impede affinity maturation and the germinal center reaction but enhance extrafollicular immunoglobulin production. J Immunol (1995) 155(3):1141–50.
78. Fischer M, Kuppers R. Human IgA- and IgM-secreting intestinal plasma cells carry heavily mutated VH region genes. Eur J Immunol (1998) 28(9):2971–7. doi:10.1002/(SICI)1521-4141(199809)28:09<2971::AID-IMMU2971>3.0.CO;2-3
79. Zheng NY, Wilson K, Wang X, Boston A, Kolar G, Jackson SM, et al. Human immunoglobulin selection associated with class switch and possible tolerogenic origins for C delta class-switched B cells. J Clin Invest (2004) 113(8):1188–201. doi:10.1172/JCI20255
80. Holder MJ, Abbot SD, Milner AE, Gregory CD, Casamayor M, Johnson GD, et al. IL-2 expands and maintains IgM plasmablasts from a CD5+ subset contained within the germinal centre cell-enriched (surface IgD-/CD39-buoyant) fraction of human tonsil. Int Immunol (1993) 5(9):1059–66. doi:10.1093/intimm/5.9.1059
82. Chanama S, Anantapreecha S, A-nuegoonpipat A, Sa-gnasang A, Kurane I, Sawanpanyalert P. Analysis of specific IgM responses in secondary dengue virus infections: levels and positive rates in comparison with primary infections. J Clin Virol (2004) 31(3):185–9. doi:10.1016/j.jcv.2004.03.005
83. Lin CF, Lei HY, Liu CC, Liu HS, Yeh TM, Wang ST, et al. Generation of IgM anti-platelet autoantibody in dengue patients. J Med Virol (2001) 63(2):143–9. doi:10.1002/1096-9071(20000201)63:2<143:AID-JMV1009>3.0.CO;2-L
84. Zidane N, Dussart P, Bremand L, Bedouelle H. Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins. BMC Infect Dis (2013) 13:302. doi:10.1186/1471-2334-13-302
85. Vazquez S, Lozano C, Perez AB, Castellanos Y, Ruiz D, Calzada N, et al. Dengue specific immunoglobulins M, A, and E in primary and secondary dengue 4 infected Salvadorian children. J Med Virol (2014) 86(9):1576–83. doi:10.1002/jmv.23833
87. Jaiswal S, Smith K, Ramirez A, Woda M, Pazoles P, Shultz LD, et al. Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice. Exp Biol Med (Maywood) (2015) 240(1):67–78. doi:10.1177/1535370214546273
88. Jianmin Z, Linn ML, Bulich R, Gentry MK, Aaskov JG. Analysis of functional epitopes on the dengue 2 envelope (E) protein using monoclonal IgM antibodies. Arch Virol (1995) 140(5):899–913. doi:10.1007/BF01314966
89. Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol (2007) 88(Pt 2):365–75. doi:10.1099/vir.0.82537-0
90. Huang X, Yue Y, Li D, Zhao Y, Qiu L, Chen J, et al. Antibody-dependent enhancement of dengue virus infection inhibits RLR-mediated Type-I IFN-independent signalling through upregulation of cellular autophagy. Sci Rep (2016) 6:22303. doi:10.1038/srep22303
91. Ubol S, Phuklia W, Kalayanarooj S, Modhiran N. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis (2010) 201(6):923–35. doi:10.1086/651018
92. Kou Z, Lim JY, Beltramello M, Quinn M, Chen H, Liu S, et al. Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes. Virology (2011) 410(1):240–7. doi:10.1016/j.virol.2010.11.007
93. Rolph MS, Zaid A, Rulli NE, Mahalingam S. Downregulation of interferon-beta in antibody-dependent enhancement of dengue viral infections of human macrophages is dependent on interleukin-6. J Infect Dis (2011) 204(3):489–91. doi:10.1093/infdis/jir271
96. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis (2010) 10(10):712–22. doi:10.1016/S1473-3099(10)70166-3
97. Gallo P, Goncalves R, Mosser DM. The influence of IgG density and macrophage Fc (gamma) receptor cross-linking on phagocytosis and IL-10 production. Immunol Lett (2010) 133(2):70–7. doi:10.1016/j.imlet.2010.07.004
98. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology (2009) 392(1):103–13. doi:10.1016/j.virol.2009.06.037
99. Steinhoff U, Muller U, Schertler A, Hengartner H, Aguet M, Zinkernagel RM. Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice. J Virol (1995) 69(4):2153–8.
100. Bachmann MF, Kundig TM, Odermatt B, Hengartner H, Zinkernagel RM. Free recirculation of memory B cells versus antigen-dependent differentiation to antibody-forming cells. J Immunol (1994) 153(8):3386–97.
101. Friberg H, Jaiswal S, West K, O’Ketch M, Rothman AL, Mathew A. Analysis of human monoclonal antibodies generated by dengue virus-specific memory B cells. Viral Immunol (2012) 25(5):348–59. doi:10.1089/vim.2012.0010
102. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE Jr. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J Virol (2014) 88(21):12233–41. doi:10.1128/JVI.00247-14
103. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE Jr. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol (2011) 86(5):2665–75. doi:10.1128/JVI.06335-11
105. Velumani S, Toh YX, Balasingam S, Archuleta S, Leo YS, Gan VC, et al. Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naive vaccinees. Hum Vaccin Immunother (2016):1–9. doi:10.1080/21645515.2015.1126012
106. Carrasco YR, Batista FD. B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity (2007) 27(1):160–71. doi:10.1016/j.immuni.2007.06.007
108. Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, Boes M, et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature (2007) 450(7166):110–4. doi:10.1038/nature06287
112. Pape KA, Catron DM, Itano AA, Jenkins MK. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity (2007) 26(4):491–502. doi:10.1016/j.immuni.2007.02.011
113. Roozendaal R, Mempel TR, Pitcher LA, Gonzalez SF, Verschoor A, Mebius RE, et al. Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity (2009) 30(2):264–76. doi:10.1016/j.immuni.2008.12.014
118. Fink K, Ng C, Nkenfou C, Vasudevan SG, van Rooijen N, Schul W. Depletion of macrophages in mice results in higher dengue virus titers and highlights the role of macrophages for virus control. Eur J Immunol (2009) 39(10):2809–21. doi:10.1002/eji.200939389
119. Limon-Flores AY, Perez-Tapia M, Estrada-Garcia I, Vaughan G, Escobar-Gutierrez A, Calderon-Amador J, et al. Dengue virus inoculation to human skin explants: an effective approach to assess in situ the early infection and the effects on cutaneous dendritic cells. Int J Exp Pathol (2005) 86(5):323–34. doi:10.1111/j.0959-9673.2005.00445.x
121. Cerny D, Haniffa M, Shin A, Bigliardi P, Tan BK, Lee B, et al. Selective susceptibility of human skin antigen presenting cells to productive dengue virus infection. PLoS Pathog (2014) 10(12):e1004548. doi:10.1371/journal.ppat.1004548
124. Sixt M, Kanazawa N, Selg M, Samson T, Roos G, Reinhardt DP, et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity (2005) 22(1):19–29. doi:10.1016/j.immuni.2004.11.013
125. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet (2012) 380(9853):1559–67. doi:10.1016/S0140-6736(12)61428-7
126. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med (2015) 373(13):1195–206. doi:10.1056/NEJMoa1506223
Keywords: dengue virus, in vivo B cell responses, plasma cells, memory B cells, antibodies
Citation: Yam-Puc JC, Cedillo-Barrón L, Aguilar-Medina EM, Ramos-Payán R, Escobar-Gutiérrez A and Flores-Romo L (2016) The Cellular Bases of Antibody Responses during Dengue Virus Infection. Front. Immunol. 7:218. doi: 10.3389/fimmu.2016.00218
Received: 11 March 2016; Accepted: 20 May 2016;
Published: 06 June 2016
Edited by:Amy Rasley, Lawrence Livermore National Laboratory, USA
Reviewed by:Marina Sandra Palermo, National Council of Scientific and Technical Research-CONICET, Argentina
Elsa Beatriz Damonte, Universidad de Buenos Aires, Argentina
Copyright: © 2016 Yam-Puc, Cedillo-Barrón, Aguilar-Medina, Ramos-Payán, Escobar-Gutiérrez and Flores-Romo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Leopoldo Flores-Romo, firstname.lastname@example.org